HC Wainwright Weighs in on BiomX Inc.’s Q2 2024 Earnings (NYSEMKT:PHGE)

BiomX Inc. (NYSEMKT:PHGE) – Equities researchers at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for shares of BiomX in a research note issued to investors on Tuesday, May 21st. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.12) per share for the quarter, down from their prior forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $2.00 target price on the stock. The consensus estimate for BiomX’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for BiomX’s Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.14) EPS and FY2024 earnings at ($0.52) EPS.

BiomX Price Performance

PHGE opened at $0.34 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The company has a 50 day moving average price of $0.36 and a two-hundred day moving average price of $0.32. The company has a market cap of $23.73 million, a PE ratio of -0.56 and a beta of 1.31.

Hedge Funds Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. Ikarian Capital LLC acquired a new stake in BiomX Inc. (NYSEMKT:PHGE) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned approximately 19.59% of BiomX at the end of the most recent reporting period. 40.57% of the stock is owned by institutional investors and hedge funds.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.